@article{Singh_2023, title={Maternal Exposure to Antidepressants Vilazodone and Vortioxetine: Effects on Neurodevelopment of Young Rat Offspring}, volume={17}, url={https://asiapharmaceutics.info/index.php/ajp/article/view/4720}, DOI={10.22377/ajp.v17i1.4720}, abstractNote={<p>Background: Vilazodone (VLZ) and Vortioxetine (VOX) are newer antidepressants often used for treating major<br>depressive disorder, but potential therapeutic safety for brain development in pregnant women is almost negligible<br>due to paucity of clinical and non-clinical data. Objectives: The current work was planned to investigate possible<br>linkages between neurodevelopmental delay and prenatal exposure to equivalent therapeutic doses of VLZ and<br>VOX. Materials and Methods: Pregnant Wistar rats were orally gavaged with VLZ and VOX (1 mg/kg, and<br>2 mg/kg body weight [BW]) from gestation day 6 to 21. The dams delivered naturally and reared their litters<br>until postnatal day 21 during which neurodevelopment reflexes were recorded. Results: Prenatally VLZ-and<br>VOX-exposed rats showed significant (1) reduction in BW, (2) delay in forelimb grasping, (3) delay in the day<br>of apparition of cliff avoidance, (4) delay in response in negative geotaxis only in VOX group, (5) deficit in grip<br>strength, and (6) delayed eye opening. Conclusion: Our findings suggest that early life exposure to VLZ and<br>VOX might be involved in the retardation and maturation of some reflexes which imply an existing association<br>between early life VLZ and VOX exposure with an increased risk of developmental vulnerability.</p>}, number={1}, journal={Asian Journal of Pharmaceutics (AJP)}, author={Singh, K. P.}, year={2023}, month={Mar.} }